Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement that its Phase 2 CELIA study for an Alzheimer's drug missed the primary endpoint. Despite Biogen calling the results "compelling," the stock dropped 6.43% on the news. The investigation focuses on whether Biogen and its executives engaged in unlawful practices. Investors affected by the stock decline are encouraged to contact the law firm regarding a possible class action lawsuit.
Biogen's investigational drug salanersen received FDA Breakthrough Therapy Designation for treating spinal muscular atrophy (SMA), based on Phase 1b study results showing improved motor function and slowed neurodegeneration in children with suboptima...
Biogen announced that it will present 14 abstracts on its nephrology portfolio, including EMPAVELI (pegcetacoplan) and investigational felzartamab, at the 63rd European Renal Association Congress and the 2026 American Transplant Congress. The data co...
